Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
6 pending office actions • 6 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Stichting Radboud Universitair Medisch Centrum has 6 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 6 examiners and 6 art units, showing broad dispersion across the active examination docket. This structure favors centralized deadline control combined with separate analysis of each examiner and technical unit.
SHIN, DANA H is the busiest examiner, with 1 pending matter. The absence of a larger identified concentration means counsel should not assume that one examiner’s approach will govern the remaining matters.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (17%) |
| §103 only | 2 (33%) |
| Multi-statute (no §101) | 3 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHIN, DANA H | 1 | 26.9% | +26.9% |
| DAVID, SHAUN L | 1 | 72.7% | +18.5% |
| SALAMON, PETER A | 1 | 86.3% | +5.9% |
| HAN, ROBIN | 1 | 33.5% | +61.8% |
| FERNANDEZ, SUSAN EMILY | 1 | 52.3% | +60.9% |
| VALLE, ERNESTO | 1 | 65.8% | +32.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18258814 | Expandable plug | DAVID, SHAUN L | 13d |
| 18571755 | Allele-specific silencing therapy for DFNA21 using antisense oligonucleotides | SHIN, DANA H | — |
| 17432278 | METHOD OF PRODUCING A BIOACTIVE SURFACE | SALAMON, PETER A | — |
| 17611912 | Improved administration of glycylcyclines by inhalation | VALLE, ERNESTO | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17922987 | VAGINAL DEVICE FOR PROLAPSE TREATMENT | HAN, ROBIN | 111d overdue |
| 17546089 | Method for ex vivo expansion CD34+HSPCs into NK cells using an aryl hydrocarbon receptor antagonist | FERNANDEZ, SUSAN EMILY | 86d overdue |
| 18258814 | Expandable plug | DAVID, SHAUN L | 13d |
| 18571755 | Allele-specific silencing therapy for DFNA21 using antisense oligonucleotides | SHIN, DANA H | — |
| 17611912 | Improved administration of glycylcyclines by inhalation | VALLE, ERNESTO | — |
| Art Unit | Apps |
|---|---|
| 1635 | 1 |
| 3771 | 1 |
| 1759 | 1 |
| 3786 | 1 |
| 1651 | 1 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18571755 | Allele-specific silencing therapy for DFNA21 using antisense oligonucleotides | SHIN, DANA H | 1635 | §101§102§103§112 | Non-Final OA | — | Pending | Dec 19, 2023 |
| 18258814 | Expandable plug | DAVID, SHAUN L | 3771 | §102§103 | Final Rejection | 13d | Pending | Jun 22, 2023 |
| 17432278 | METHOD OF PRODUCING A BIOACTIVE SURFACE | SALAMON, PETER A | 1759 | §102§112 | Final Rejection | — | Pending | Mar 20, 2023 |
| 17922987 | VAGINAL DEVICE FOR PROLAPSE TREATMENT | HAN, ROBIN | 3786 | §103 | Final Rejection | 111d overdue | Pending | Nov 03, 2022 |
| 17546089 | Method for ex vivo expansion CD34+HSPCs into NK cells using an aryl hydrocarbon receptor antagonist | FERNANDEZ, SUSAN EMILY | 1651 | §103 | Non-Final OA | 86d overdue | Pending | Dec 09, 2021 |
| 17611912 | Improved administration of glycylcyclines by inhalation | VALLE, ERNESTO | 1623 | §103§112 | Non-Final OA | — | Pending | Nov 17, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialStichting Radboud Universitair Medisch Centrum has 6 pending office actions as of October 2026, spread across 6 art units and 6 examiners.
Dana H Shin has the most, with 1 of Stichting Radboud Universitair Medisch Centrum's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
